This site is intended for US eye care professionals only.

Flexible dosing with as few as 6 injections per year1

Preparation steps for administering SYFOVRE

View Transcript   ▼

This video provides information about how to prepare for SYFOVRE administration.

SYFOVRE is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation. We will cover additional Important Safety Information for SYFOVRE later in this video.

The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days. Store SYFOVRE in the refrigerator between 2 degrees Celsius to 8 degrees Celsius, 36 degrees Fahrenheit to 46 degrees Fahrenheit. Remove the carton from the refrigerator, keeping the vial in the original carton to protect from light.

Prior to injection, allow the carton to come to room temperature, 20 degrees Celsius to 25 degrees Celsius, 68 degrees Fahrenheit to 77 degrees Fahrenheit for at least 15 minutes, but no longer than 8 hours, which may help prevent increased injection forces. Fill the syringe immediately prior to the injection.

It’s important to not shake the vial. The vial is for use in a single eye.

Inspect the solution. It should be a clear, colorless to light yellow aqueous solution. Do not use if:

  • particulates, cloudiness, or discoloration are visible
  • the vial shows signs of damage or tampering,
  • or if the expiration date has passed

STEP 1

Gather the supplies needed:

  • One SYFOVRE vial, (included in the product box)

Additional supplies needed:

  • IVT Injection Kit, (which is provided by Apellis). The injection kit includes:
    • One sterile 5-micron filter needle
    • One sterile ½ inch: 29-gauge thin-wall injection needle with Luer-lock hub or a 27-gauge needle with Luer-lock hub
  • Note: Increased injection forces and/or increased injection time could be experienced if a smaller diameter injection needle is used (for example, a 30-gauge)
  • You will also need one sterile 1-mL Luer-lock syringe with a 0.1 mL dose mark
  • Lastly, you’ll need an alcohol swab

Use aseptic technique to carry out the following preparation steps:

STEP 2

Remove the flip-off cap from the vial and clean the vial septum with an alcohol swab. Wait for the alcohol to dry out.

STEP 3

Attach the 5-micron filter needle onto a 1-mL Luer-lock syringe by twisting it onto the Luer-lock syringe tip.

STEP 4

Push the filter needle into the center of the vial septum until the needle is submerged in the drug product to prevent withdrawal of air. To withdraw the entire contents of the vial into the syringe, hold the vial at a slightly inclined position. Withdraw the drug product slowly to prevent air bubbles. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid until all of the fluid is withdrawn from the vial. Do not tap the syringe to remove air bubbles. While maintaining the filter needle within the vial, invert the syringe and move the plunger down and up until bubbles move to the top.

STEP 5

Using aseptic technique, disconnect the filter needle from the syringe and dispose of it. Do not use the filter needle for injection.

STEP 6

Aseptically and firmly attach the injection needle onto the 1-mL Luer-lock syringe.

STEP 7

Check for air bubbles by holding the syringe with the needle pointing up. Do not tap the syringe to remove air bubbles. To remove any air bubbles and/or prepare the syringe for injection, remove the needle cap and with the needle end facing up gently advance the plunger to the 0.1 mL dose mark. Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed. The syringe is now ready for injection. Ensure that the injection is given immediately after the preparation of the dose. Any unused medicinal product or waste material should be disposed of in accordance with local regulations. For additional information, including injection procedure, see Dosage and Administration, Section 2, of the SYFOVRE full Prescribing Information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age–related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full Prescribing Information on SyfovreECP.com.

For more information about SYFOVRE, visit SyfovreECP.com

Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed. Ensure that the injection is given immediately after the preparation of the dose.

Prior to the intravitreal injection, patients should be monitored for elevated intraocular pressure (IOP) using tonometry. If necessary, ocular hypotensive medication can be given to lower the IOP.

The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid, and ocular surface should be administered prior to the injection.

Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.1 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.

Immediately following the intravitreal injection, patients should be monitored for elevations in IOP. Additional evaluation may include checking for perfusion of the optic nerve head and tonometry. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Each vial should only be used for the treatment of a single eye. If the fellow eye requires treatment, a new sterile, vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before SYFOVRE administration. Repeat same procedure steps as above.

Any unused medicinal product or waste material should be disposed of in accordance with local regulations.

SYFOVRE® (pegcetacoplan injection) recommended dosing schedule is once every 25 to 60 days. SYFOVRE® (pegcetacoplan injection) recommended dosing schedule is once every 25 to 60 days.
  • SYFOVRE must be administered by a qualified physician1
  • The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days1
  • For additional information, see DOSAGE AND ADMINISTRATION, section 2, in the SYFOVRE full Prescribing Information

There were no clinically significant differences on the pharmacokinetics of SYFOVRE intravitreal administration based on age (60 to 97 years), gender, renal impairment, and hepatic function1

SYFOVRE allows customization based on your patients' needs

SYFOVRE® (pegcetacoplan injection) product image

Download the Preparation for Administration Brochure to learn more

SYFOVRE® (pegcetacoplan injection) preparation for administration brochure

Preparation for Administration Brochure resource thumb

Reference:  1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2023.

Show more Show less

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).